Trial Profile
An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 May 2017
Price :
$35
*
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use